Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Summary

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.  The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Gastrointestinal, Genetic Disorders and Other Diseases which include indications Colorectal Cancer, Familial Adenomatous Polyposis, Hepatic (Liver) Tumor, Liver Fibrosis, Melanoma, Orphan Diseases, Ovarian Cancer, Pancreatic Cancer, Scar and Solid Tumor. 

Furthermore, this report also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview 7
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development 21
Boston Biomedical Inc 21
Dicerna Pharmaceuticals Inc 21
Marina Biotech Inc 21
Propanac Biopharma Inc 22
Warp Drive Bio Inc 22
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles 23
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
BBI-801 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
exisulind - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
M-101 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
M-102 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
M-201 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
nefopam hydrochloride - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Oligonucleotides for Hepatoblastoma - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PRP - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit Beta-Catenin for Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
WX-024 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products 43
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones 45
Featured News & Press Releases 45
Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP 45
Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies 45
Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study 46
Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP 47
Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China 48
Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017 48
Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer 49
Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application 50
May 19, 2017: Propanc Biopharma Highlights PRP's Potential to Reprogram Cancer Stem Cells 50
May 16, 2017: Propanc Biopharma Awaits FDA Response to Orphan Drug Designation Request for Treatment of Pancreatic Cancer, as PRP Progresses to First-In-Human Studies 51
May 02, 2017: Propanc Biopharma Provides Update on Investigational Medicinal Product Manufacture of PRP for First-In-Human Studies 52
Apr 27, 2017: Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP 53
Apr 04, 2017: Boston Biomedical Presents New Preclinical Data on BBI-801 at AACR 2017 Highlighting the Potential Role of Cancer Stemness Inhibition 53
Feb 14, 2017: Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study 54
Jan 24, 2017: Propanc Provides Progress Update on Additional Patent Applications 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Number of Products under Investigation by Universities/Institutes, H2 2017 13
Products under Investigation by Universities/Institutes, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Pipeline by Boston Biomedical Inc, H2 2017 21
Pipeline by Dicerna Pharmaceuticals Inc, H2 2017 21
Pipeline by Marina Biotech Inc, H2 2017 22
Pipeline by Propanac Biopharma Inc, H2 2017 22
Pipeline by Warp Drive Bio Inc, H2 2017 22
Dormant Products, H2 2017 43
Dormant Products, H2 2017 (Contd..1), H2 2017 44